Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00753454 · ClinicalTrials.gov registry record · Phase 3
Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)
A Phase 3 study, sponsored by UCB Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 168
- Enrollment target
NCT00753454 is a Phase 3 study that has completed, run by UCB Pharma. The registered enrollment target is 168 participants.
The verdict
NCT00753454, a Phase 3 study, has completed, sponsored by UCB Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (MTX).
Interventions
- DRUG Certolizumab pegol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2008-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00753454
The ClinicalTrials.gov registry entry for NCT00753454 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is UCB Pharma, which has 100 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Certolizumab pegol is the first listed.
NCT00753454 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00753454 about?
NCT00753454 is a clinical study titled "Open Label Extension for Patients Coming From the Dosing Flexibility Study in Patients With Rheumatoid Arthritis (RA)". The purpose of this study is to continue to assess the safety of certolizumab pegol in combination with methotrexate (MTX).
What is the current status of trial NCT00753454?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 168 participants. The study started on 2008-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00753454?
The interventions under investigation include: Certolizumab pegol (DRUG).
Who is sponsoring clinical trial NCT00753454?
This trial is sponsored by UCB Pharma, which has 100 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.